NIH's Role In Sustaining the U.S. Economy 2021 Update Now Available
here
UMR Urges House and Senate Leaders to Include NIH Funding in COVID Relief Package
read here
UMR releases new fact sheets on COVID-19 and biomedical research. Read
here
See how UMR members are aiding in the fight against the coronavirus
here
A new episode of the
Amazing Things Podcast is now available! Check it out
here.
Johnson & Johnson Announces Submission of Application to the U.S. FDA for Emergency Use Authorization of its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
February 4, 2021 – Johnson & Johnson today announced that Janssen Biotech, Inc., has submitted an application to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for its investigational single-dose Janssen COVID-19 vaccine candidate. Johnson & Johnson intends to distribute vaccine to the U.S. government immediately following authorization, and expects to supply 100 million doses to the U.S. in the first half of 2021.
